---
title: Cerebroprotein Hydrolysate + Piracetam
description: >-
  Cerebroprotein Hydrolysate + Piracetam is prescribed as an adjunctive therapy
  for improving cognitive function and supporting neurological recovery in
  conditions such as stroke, head injury, and Alzheimer's disease.  It is also
  used to treat cortical myoclonus and cerebrocortical insufficiency. P...
is_banned: false
lastModified: '2025-09-22T17:22:08.616Z'
faqs:
  - q: >-
      What is the recommended dosage for Cerebroprotein Hydrolysate +
      Piracetam?**


      **A:**  The standard adult dosage is Cerebroprotein Hydrolysate 10-60 mL
      IV infusion and Piracetam 800-2400 mg orally per day, divided into
      multiple doses.  Pediatric and geriatric dosages should be adjusted based
      on individual patient needs and clinical response. Patients with renal or
      hepatic impairment require careful dosage modifications.
    a: >-
      A:**  The standard adult dosage is Cerebroprotein Hydrolysate 10-60 mL IV
      infusion and Piracetam 800-2400 mg orally per day, divided into multiple
      doses.  Pediatric and geriatric dosages should be adjusted based on
      individual patient needs and clinical response. Patients with renal or
      hepatic impairment require careful dosage modifications.
  - q: >-
      What are the primary uses of this combination therapy?**


      **A:** Primarily used to support cognitive function and neurological
      recovery in conditions like stroke, head injury, and Alzheimer's disease,
      it is also used for myoclonus and cerebrocortical insufficiency.
    a: >-
      A:** Primarily used to support cognitive function and neurological
      recovery in conditions like stroke, head injury, and Alzheimer's disease,
      it is also used for myoclonus and cerebrocortical insufficiency.
  - q: >-
      What is the mechanism of action for each component?**


      **A:** Cerebroprotein Hydrolysate acts as a neurotrophic factor,
      supporting neuronal growth and survival. Piracetam's mechanism is not
      fully understood but is thought to involve improved cerebral blood flow
      and neurotransmitter modulation.
    a: >-
      A:** Cerebroprotein Hydrolysate acts as a neurotrophic factor, supporting
      neuronal growth and survival. Piracetam's mechanism is not fully
      understood but is thought to involve improved cerebral blood flow and
      neurotransmitter modulation.
  - q: >-
      Are there any serious side effects doctors should be aware of?**


      **A:** While generally well-tolerated, rare but serious side effects
      include allergic reactions, worsening of neurological conditions,
      hallucinations, and confusion.  Any severe or persistent side effects
      should be considered an ADR and require prompt medical attention.
    a: >-
      A:** While generally well-tolerated, rare but serious side effects include
      allergic reactions, worsening of neurological conditions, hallucinations,
      and confusion.  Any severe or persistent side effects should be considered
      an ADR and require prompt medical attention.
  - q: >-
      What are the contraindications for prescribing this combination?**


      **A:**  Contraindications include hypersensitivity to either component,
      severe renal impairment (for Cerebroprotein Hydrolysate), status
      epilepticus, hemorrhagic diathesis, and Huntington's chorea (for
      Piracetam).
    a: >-
      A:**  Contraindications include hypersensitivity to either component,
      severe renal impairment (for Cerebroprotein Hydrolysate), status
      epilepticus, hemorrhagic diathesis, and Huntington's chorea (for
      Piracetam).
  - q: >-
      What drug interactions should be considered?**


      **A:**  Clinically significant interactions can occur with antidepressants
      (especially MAOIs), anticoagulants, alcohol, and thyroid medications.
      Concomitant use of CNS stimulants or depressants should also be carefully
      evaluated.
    a: >-
      A:**  Clinically significant interactions can occur with antidepressants
      (especially MAOIs), anticoagulants, alcohol, and thyroid medications.
      Concomitant use of CNS stimulants or depressants should also be carefully
      evaluated.
  - q: >-
      Can this combination be prescribed during pregnancy or breastfeeding?**


      **A:**  Use with caution during pregnancy and breastfeeding only if the
      potential benefits outweigh the risks. Safety profiles are not
      well-established, consult with a specialist.
    a: >-
      A:**  Use with caution during pregnancy and breastfeeding only if the
      potential benefits outweigh the risks. Safety profiles are not
      well-established, consult with a specialist.
  - q: >-
      What monitoring parameters are recommended during treatment?**


      **A:** Monitor cognitive function, neurological status, renal function,
      and blood pressure. Liver function monitoring might be necessary depending
      on patient-specific factors and co-existing medical conditions.
    a: >-
      A:** Monitor cognitive function, neurological status, renal function, and
      blood pressure. Liver function monitoring might be necessary depending on
      patient-specific factors and co-existing medical conditions.
  - q: >-
      What are some common side effects patients might experience?**


      **A:** Common side effects include headache, nausea, dizziness, vertigo,
      increased sweating, nervousness, and weight gain.
    a: >-
      A:** Common side effects include headache, nausea, dizziness, vertigo,
      increased sweating, nervousness, and weight gain.
  - q: >-
      Are there specific dosage adjustments needed for elderly patients?**


      **A:** Yes, elderly patients should typically start with a lower dose,
      with adjustments made as needed based on tolerability and clinical
      response. Age-related decline in renal function should also be considered.
    a: >-
      A:** Yes, elderly patients should typically start with a lower dose, with
      adjustments made as needed based on tolerability and clinical response.
      Age-related decline in renal function should also be considered.
---
## **Usage**

Cerebroprotein Hydrolysate + Piracetam is prescribed as an adjunctive therapy for improving cognitive function and supporting neurological recovery in conditions such as stroke, head injury, and Alzheimer's disease.  It is also used to treat cortical myoclonus and cerebrocortical insufficiency. Piracetam is classified as a nootropic agent, while cerebroprotein hydrolysate is a neurotrophic agent.  The combination aims to enhance nerve repair and neuronal survival.

## **Alternate Names**

This combination is sometimes referred to as Cerebrolysin + Piracetam or Cerebroprotein Hydrolysate and Piracetam combination. Brand names include Cerebrain Plus, Ceremax Plus, and CEREGIS GOLD.

## **How It Works**

**Cerebroprotein Hydrolysate:**

* **Pharmacodynamics:** Acts as a neurotrophic factor, promoting neuronal survival, growth, and differentiation by mimicking the actions of endogenous neurotrophic factors, such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF).  It stimulates neurogenesis and synaptogenesis.
* **Pharmacokinetics:** Administered intravenously. Distribution, metabolism, and elimination are not fully characterized.

**Piracetam:**

* **Pharmacodynamics:**  The exact mechanism is not fully understood. It's believed to improve cerebral blood flow, enhance neuronal metabolism, and modulate neurotransmitter systems, possibly by influencing membrane fluidity.
* **Pharmacokinetics:** Administered orally. Well-absorbed, reaching peak plasma concentrations in 1-1.5 hours. It is not significantly metabolized in the liver and is primarily excreted renally with a half-life of approximately 5 hours.

## **Dosage**

### **Standard Dosage**

#### **Adults:**

Cerebroprotein Hydrolysate: 10-60 mL IV infusion.

Piracetam: 800-2400 mg orally per day, divided into multiple doses.

The duration of treatment depends on the patient's condition and response to therapy.

#### **Children:**

Limited information is available regarding pediatric dosing, its use is generally not recommended for children under 16 years of age. If used, dosing should be carefully determined by a physician based on the child's weight and age, with cautious consideration of potential risks and benefits.

#### **Special Cases:**

* **Elderly Patients:**  Start with a lower dose and adjust as needed based on tolerability and clinical response. Consider age-related decline in renal function.
* **Patients with Renal Impairment:** Dosage adjustments are necessary. For severe renal impairment, Cerebroprotein Hydrolysate is contraindicated, and Piracetam dosage requires reduction.
* **Patients with Hepatic Dysfunction:** Caution is advised. Adjust Piracetam dose as needed.
* **Patients with Comorbid Conditions:** Individualized dosing based on the specific comorbid conditions (e.g., diabetes, cardiovascular disease) and potential drug interactions.

### **Clinical Use Cases**

Dosages in specialized settings (Intubation, Surgical Procedures, Mechanical Ventilation, Intensive Care Unit (ICU) Use, Emergency Situations) should be determined by the attending physician, considering patient-specific factors and the severity of the condition.  Close monitoring is crucial.

### **Dosage Adjustments**

Dose modifications are based on renal/hepatic function, patient age, comorbid conditions, and other factors influencing drug metabolism. Genetic polymorphisms affecting drug metabolism should also be considered.

## **Side Effects**

### **Common Side Effects**

Headache, nausea, dizziness, vertigo, increased sweating, nervousness, weight gain, abnormality of voluntary movements.

### **Rare but Serious Side Effects**

Allergic reactions (rash, itching, difficulty breathing, swelling), worsening of existing neurological conditions, hallucinations, confusion, agitation, fever.

### **Long-Term Effects**

Long-term effects are not fully elucidated and require further research.

### **Adverse Drug Reactions (ADR)**

Any severe or persistent side effects, particularly allergic reactions, should be considered an ADR and require prompt medical attention.


## **Contraindications**

Hypersensitivity to Cerebroprotein Hydrolysate or Piracetam, severe renal impairment (Cerebroprotein Hydrolysate), status epilepticus, hemorrhagic diathesis, Huntington's chorea (Piracetam), hepatic impairment (Piracetam).

## **Drug Interactions**

Antidepressants (especially MAOIs), anticoagulants and antiplatelet agents, alcohol, thyroid hormones. CNS stimulants and depressants.

## **Pregnancy and Breastfeeding**

Both Cerebroprotein Hydrolysate and Piracetam should be used with extreme caution during pregnancy and breastfeeding only if the potential benefits clearly outweigh the risks.  Their safety profiles in these situations are not well-established.

## **Drug Profile Summary**

* **Mechanism of Action:** Cerebroprotein Hydrolysate: Neurotrophic agent; Piracetam: Nootropic.
* **Side Effects:** Headache, nausea, dizziness, nervousness, weight gain, abnormality of voluntary movements.
* **Contraindications:** Hypersensitivity, severe renal impairment, status epilepticus, hemorrhagic diathesis, Huntington's chorea.
* **Drug Interactions:** Antidepressants, anticoagulants, alcohol, thyroid hormones.
* **Pregnancy & Breastfeeding:** Use with extreme caution if benefits outweigh risks. Consult a specialist.
* **Dosage:** Adult: Cerebroprotein Hydrolysate 10-60 mL IV, Piracetam 800-2400 mg orally daily. Pediatric dosing should be determined by a physician and is generally avoided.
* **Monitoring Parameters:** Cognitive function, neurological status, renal function, blood pressure, liver function (if applicable).

## **Popular Combinations**

Sometimes used with other nootropics or in combination with citicoline.

## **Precautions**

* **General Precautions:**  Pre-screening for allergies, metabolic disorders, organ dysfunction. Monitoring of renal function and blood pressure is recommended. Exercise caution in patients with liver disease, high blood pressure, or cardiovascular disease.
* **Specific Populations:**  Consult a specialist before prescribing to pregnant or breastfeeding women due to limited safety information.  Use with caution in children and the elderly, adjusting dosage as needed.
* **Lifestyle Considerations:** Advise patients to avoid alcohol as it may exacerbate side effects, especially dizziness. Caution patients about potential drowsiness and its effects on driving or operating machinery.

## **FAQs (Frequently Asked Questions)**

### **Q1: What is the recommended dosage for Cerebroprotein Hydrolysate + Piracetam?**

**A:**  The standard adult dosage is Cerebroprotein Hydrolysate 10-60 mL IV infusion and Piracetam 800-2400 mg orally per day, divided into multiple doses.  Pediatric and geriatric dosages should be adjusted based on individual patient needs and clinical response. Patients with renal or hepatic impairment require careful dosage modifications.

### **Q2: What are the primary uses of this combination therapy?**

**A:** Primarily used to support cognitive function and neurological recovery in conditions like stroke, head injury, and Alzheimer's disease, it is also used for myoclonus and cerebrocortical insufficiency.

### **Q3:  What is the mechanism of action for each component?**

**A:** Cerebroprotein Hydrolysate acts as a neurotrophic factor, supporting neuronal growth and survival. Piracetam's mechanism is not fully understood but is thought to involve improved cerebral blood flow and neurotransmitter modulation.


### **Q4: Are there any serious side effects doctors should be aware of?**

**A:** While generally well-tolerated, rare but serious side effects include allergic reactions, worsening of neurological conditions, hallucinations, and confusion.  Any severe or persistent side effects should be considered an ADR and require prompt medical attention.

### **Q5: What are the contraindications for prescribing this combination?**

**A:**  Contraindications include hypersensitivity to either component, severe renal impairment (for Cerebroprotein Hydrolysate), status epilepticus, hemorrhagic diathesis, and Huntington's chorea (for Piracetam).

### **Q6: What drug interactions should be considered?**

**A:**  Clinically significant interactions can occur with antidepressants (especially MAOIs), anticoagulants, alcohol, and thyroid medications. Concomitant use of CNS stimulants or depressants should also be carefully evaluated.

### **Q7: Can this combination be prescribed during pregnancy or breastfeeding?**

**A:**  Use with caution during pregnancy and breastfeeding only if the potential benefits outweigh the risks. Safety profiles are not well-established, consult with a specialist.

### **Q8: What monitoring parameters are recommended during treatment?**

**A:** Monitor cognitive function, neurological status, renal function, and blood pressure. Liver function monitoring might be necessary depending on patient-specific factors and co-existing medical conditions.


### **Q9: What are some common side effects patients might experience?**

**A:** Common side effects include headache, nausea, dizziness, vertigo, increased sweating, nervousness, and weight gain.


### **Q10: Are there specific dosage adjustments needed for elderly patients?**

**A:** Yes, elderly patients should typically start with a lower dose, with adjustments made as needed based on tolerability and clinical response. Age-related decline in renal function should also be considered.

